Author:
Zhong GuoFu,Chen Junteng,Li Yangtao,Han Yue,Wang Maosheng,Nie Qinqi,Xu Mujuan,Zhu Qinghua,Chang Xiao,Wang Ling
Abstract
Abstract
Background
Ginsenoside Rg3 is a component of ginseng that protects against myocardial ischemia/reperfusion (MI/R) injury. Ferroptosis is a new form of cell death characterized by oxidative damage to phospholipids. The purpose of this study was to examine the role and of ginsenoside Rg3 in MI/R and the mechanism.
Methods
A mouse model of left anterior descending (LAD) ligation-induced myocardial ischemia/reperfusion (MI/R) injury and oxygen-glucose deprivation/reperfusion (OGD/R) were used as in vitro and in vivo models, respectively. Echocardiographic analysis, 2,3,5-triphenyltetrazolium chloride (TTC) staining and hematoxylin-eosin (H&E) staining were used to assess the cardioprotective effects of ginsenoside Rg3. Western blotting, biochemical analysis, small interfering RNA analysis and molecular docking were performed to examine the underlying mechanism.
Results
Ginsenoside Rg3 improved cardiac function and infarct size in mice with MI/R injury. Moreover, ginsenoside Rg3 increased the expression of the ferroptosis-related protein GPX4 and inhibited iron deposition in mice with MI/R injury. Ginsenoside Rg3 also activated the Nrf2 signaling pathway. Ginsenoside Rg3 attenuated myocardial ischemia/reperfusion-induced ferroptosis via the Nrf2 signaling pathway. Notably, ginsenoside Rg3 regulated the keap1/Nrf2 signaling pathway to attenuate OGD/R-induced ferroptosis in H9C2 cells. Taken together, ginsenoside Rg3 attenuated myocardial ischemia/reperfusion-induced ferroptosis via the keap1/Nrf2/GPX4 signaling pathway.
Conclusions
Our findings demonstrated that ginsenoside Rg3 ameliorate MI/R-induced ferroptosis via the keap1/Nrf2/GPX4 signaling pathway.
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Yao H, Xie Q, He Q, Zeng L, Long J, Gong Y, Li X, Li X, Liu W, Xu Z, et al. Pretreatment with Panaxatriol Saponin attenuates mitochondrial apoptosis and oxidative stress to Facilitate Treatment of Myocardial Ischemia-Reperfusion Injury via the regulation of Keap1/Nrf2 activity. Oxidative Med Cell Longev. 2022;2022:1–20.
2. Hausenloy DJ, Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest. 2013;123(1):92–100.
3. Zeng J-j, Shi H-q, Ren F-f, Zhao X-s, Chen Q-y, Wang D-j, Wu L-p, Chu M-p, Lai T-f, Li L. Notoginsenoside R1 protects against myocardial ischemia/reperfusion injury in mice via suppressing TAK1-JNK/p38 signaling. Acta Pharmacol Sin. 2023;44(7):1366–79.
4. Zhao W-k, Zhou Y, Xu T-t, Wu Q, Li H. Ferroptosis: opportunities and challenges in Myocardial Ischemia-Reperfusion Injury. Oxidative Med Cell Longev. 2021;2021:1–12.
5. Bersuker K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, Roberts MA, Tong B, Maimone TJ, Zoncu R, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. 2019;575(7784):688–92.